![](/assets/artwork/1x1-42817eea7ade52607a760cbee00d1495.gif)
72 episodes
![](/assets/artwork/1x1-42817eea7ade52607a760cbee00d1495.gif)
Life Science Today Noah Goodson, PhD
-
- Science
-
-
5.0 • 7 Ratings
-
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
-
Final Episode
This week, I have an announcement to make. Find out more athttps://LifeScienceTodayPodcast.comAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolvi...
-
Sanofi/Takeda, UniQure & CSL, Fog Pharma, Merck + Imago
Vaccine hesitancy, the most expensive gene therapy in the world, a $178M series D, and a $1.3B buyoutFind out more athttps://LifeScienceTodayPodcast.comStory ReferencesSanofi/TakedaUniQure & CSLFog PharmaMerck + Imago About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how t...
-
Indivior + Opiant, Regeneron + CytomX, Rezo, Provention
A $145M opioid acquisition, biobucks for the holidays, a series A, and diabetes approvalsFind out more athttps://LifeScienceTodayPodcast.comStory ReferencesIndivior + OpiantRegeneron + CytomXRezoProventionAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market r...
-
Intellia, Regeneron, Viatris + Oyster Point
More CRISPR data, oncology wins, and a new player in ophthalmologyFind out more athttps://LifeScienceTodayPodcast.comStory ReferencesIntelliaRegeneronViatris + Oyster PointAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Sci...
-
Sumitovant + Myovant, Thermo Fisher + Binding Site Group, Astellas & Taysha, Agios, Vaxctye
Billion-dollar acquisitions, troubled waters for some biotech’s, and a prosperous outlook for othersFind out more athttps://LifeScienceTodayPodcast.comStory ReferencesSumitovant + MyovantThermo Fisher + Binding Site GroupAstellas & TayshaAgiosVaxctyeAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capit...
-
FDA, AbbVie + DJS, Roche + Hookipa, Kyverna
Some statistically significant guidance, seed to acquisition, some biobucks, and the CART of the future. Find out more athttps://LifeScienceTodayPodcast.comStory References FDAAbbVie + DJSRoche + HookipaKyvernaAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock mar...
Customer Reviews
Brilliant insights
Dr. Goodson holds your attention brilliantly through clear and direct information without sacrificing substance. His expertise is on display each episode through sound explanations of complex movements within the biotech and pharmaceutical worlds. This podcast is perfect for the novice as well as expert relating to these topics of discussion. I highly recommend this be a regular in your podcast rotation!
Not only informative but also entertaining!
Dr Goodson brilliantly delivers scientific updates in a manner absent of confusing jargon, making it approachable to everyone. He also injects a bit of his educational discernment but still remains neutral. The short updates are perfect and I'm looking forward to more.
to the point
speaker is clear, easy to understand, length is good, content relevant. ads not intrusive